Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Equity Income (2022 - 2024)

Caribou Biosciences (CRBU) has disclosed Equity Income for 3 consecutive years, with -$14000.0 as the latest value for Q3 2024.

  • Quarterly Equity Income fell 250.0% to -$14000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was -$125000.0 through Sep 2024, down 119.3% year-over-year, with the annual reading at -$6000.0 for FY2023, 95.49% up from the prior year.
  • Equity Income for Q3 2024 was -$14000.0 at Caribou Biosciences, up from -$102000.0 in the prior quarter.
  • The five-year high for Equity Income was $31000.0 in Q3 2022, with the low at -$102000.0 in Q2 2024.
  • Average Equity Income over 3 years is -$25500.0, with a median of -$14500.0 recorded in 2023.
  • The sharpest move saw Equity Income skyrocketed 237.5% in 2023, then crashed 563.64% in 2024.
  • Over 3 years, Equity Income stood at -$60000.0 in 2022, then skyrocketed by 85.0% to -$9000.0 in 2023, then crashed by 55.56% to -$14000.0 in 2024.
  • According to Business Quant data, Equity Income over the past three periods came in at -$14000.0, -$102000.0, and -$9000.0 for Q3 2024, Q2 2024, and Q4 2023 respectively.